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Abstract
Background Urinary interleukin-18 and cystatin-C are
suggested to be biomarkers for predicting acute kidney
injury (AKI). The aims of this study are to examine
whether the urinary concentrations of interleukin-18 and
cystatin-C vary with gestational age and other factors in
non-AKI control neonates, and to determine whether
urinary interleukin-18 and cystatin-C can predict AKI
development in non-septic critically ill neonates, inde-
pendently of potential confounders.
Methods We enrolled 62 non-septic critically ill neonates.
Urine was collected every 48–72 h during the first 10 days
of life.
Results Urinary concentration of cystatin-C, but not
interleukin-18, decreased with increasing gestational age and
body weight, but not with increasing postnatal age in non-AKI
control neonates. Both urinary interleukin-18 and cystatin-C
were associated with AKI, even after controlling for gestational
and postnatal age, birth weight, gender, Apgar score and the
score for neonatal acute physiology in non-septic critically ill
neonates. Urinary interleukin-18 and cystatin-C had odds ratios
of 2.27 and 2.07, and achieved the area under-the-receiver-
operating-characteristic curve of 0.72 and 0.92, respectively,
for predicting AKI.
Conclusions The urinary concentration of cystatin-C, but not
interleukin-18, may decrease with increasing renal maturity.
Both urinary interleukin-18 and cystatin-C are independently
predictive of AKI in non-septic critically ill neonates.
Keywords Acutekidneyinjury.Critically illneonates.
Diagnostictest.Urinarybiomarkers.Urinary cystatin-C.
Urinaryinterleukin-18
Introduction
Acute kidney injury (AKI) is an independent risk factor for
mortality [1]. Critically ill neonates are at a high risk of
having AKI, as they are commonly exposed to perinatal
anoxia/hypoxia and nephrotoxic medications and have fre-
quent infections that lead to multi-organ failure [2, 3]. The
estimated reported incidence of AKI in critically ill neonates
ranges from 8 to 24% and the mortality rate is between 10
and 61% [4]. The exact incidence of AKI in neonates,
however, is unknown, because there is a lack of a classifi-
cation system to define AKI in the neonatal population [3].
Efforts to define and characterize AKI in neonates, leading
to the detection of early AKI, will ultimately contribute to an
improvement in neonatal outcome.
Serum creatinine (Cr) is the most commonly used clinical
measure of renal function, but it is a poor marker for diag-
nosis of AKI. The use of serum Cr in neonates, especially in
premature neonates, is further complicated by maturational
change during postnatal renal development [3]. There is a
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nates. Serum Cr reflects maternal levels during the first
2 days of life. In full-term healthy neonates, the glomerular
filtration rate (GFR) rapidly increases and the serum Cr
declines progressively with increasing postnatal age to
reach a stable neonatal level by 2 weeks of life [5, 6].
Serum Cr, however, does not fall steadily from birth in
very preterm neonates. In neonates with less than 26 weeks
of gestational age, there is a transient increase in serum Cr,
r e a c h i n gap e a ko nd a y3o fl i f e ,f o l l o w e db yap r o g r e s s i v e
decline [6, 7].
Recent research in AKI has focused on identifying bio-
markers, characterized as early, noninvasive, and sensitive
indicators of AKI. The early detection of AKI could opti-
mize and improve patient outcomes [8–10]. Two of the most
promising biomarkers of AKI are urinary interleukin-18
(uIL-18) [11–13] and urinary cystatin-C (uCysC) [14, 15],
although there is inconsistent evidence regarding the predic-
tive role of these biomarkers [16, 17]. Urinary IL-18 has the
potential to diagnose AKI within hours of an insult. Unlike
serum Cr, IL-18 is an 18-kDa pro-inflammatory cytokine
that is induced in the proximal tubule after AKI, and
released into urine after cleavage by caspase-1 [18–20].
Previous studies in both critically ill children and adults
revealed that uIL-18 concentrations rise 24–48 h prior to
AKI defined by risk, injury, failure, loss, end-stage renal
disease (RIFLE) criteria [12, 21]. In critically ill children
without sepsis, uIL-18 is a reliable test for early diagnosis of
AKI and independently predicts the severity of AKI and
mortality [21].
CysC, a 13-kDa protein, is normally filtered freely and
has been proposed as a promising endogenous marker of
GFR in both adults and children [22, 23]. It is consid-
ered to be completely reabsorbed and catabolized in the
proximal tubule. CysC is therefore not normally found in
urine in significant amounts. The appearance of in-
creased concentrations of CysC in urine may reflect
renal tubular injury and impairment [24, 25]. Studies in
adults undergoing cardiothoracic surgery and in general
critically ill adults demonstrate that uCysC is an early
predictor of AKI and an independent predictor of mor-
tality [14, 15].
Both uIL-18 and uCysC are detectable in neonates
[26]. There is an additional challenge in the discovery
of early biomarkers of AKI in this population due to the
maturational change of biomarkers during renal devel-
opment [3]. Two interesting clinical studies published
recently have demonstrated that the baseline value of
uCysC, but not uIL-18, varies by gestational age in
premature infants [26]. In very low birth weight Infants,
the urinary level of CysC, but not of IL-18, was asso-
ciated with AKI during the early postnatal period [27].
However, the previous studies were performed in
premature infants, including infants with sepsis, and it
has been suggested that sepsis is significantly associated
w i t ht h el e v e l so fb o t hu I L - 1 8a n du C y s C[ 14, 19]. We
therefore designed the present study to test the hypoth-
esis that both uIL-18 and uCysC might predict AKI
development in non-septic critically ill neonates.
The aims of the present study are (1) to examine whether
the concentration of IL-18 and CysC varies with gestational
and postnatal age, birth weight, body weight, gender, Apgar
score, and the score for neonatal acute physiology (SNAP)
in non-AKI control neonates during the first 10 days of life,
(2) to determine the association between the urinary bio-
markers and AKI in non-septic critically ill neonates, and (3)
to evaluate whether uIL-18 and uCysC could serve as early
predictorsofAKIinthispopulation,independentlyofpotential
confounders.
Patients and methods
Subject selection
All neonates admitted to the neonatal intensive care unit
(NICU) on the first 3 days of life during the period from
August to December 2010 were eligible for this prospective
study. We excluded neonates with known congenital abnor-
mality of the kidney, neonates with clinical diagnosis of
infection, neonates undergoing exchange transfusion, and
neonates with less than two serum Cr measurements. The
Institutional Review Board at the Children’s Hospital affil-
iated to Soochow University approved the study. Informed
parental consent was obtained at enrollment of each
neonate.
Clinical data collection
Maternal data collected included pregnancy complication,
medication, and mode of delivery. Neonatal data collected
included gestational age, birth weight, Apgar score, and
delivery room resuscitation course. Gestational age was
calculated from the mother’s menstrual history and was
confirmed by ultrasonography. SNAP was calculated on
the day of NICU admission [28]. Clinical laboratory results
such as serum electrolytes, Cr, blood urea nitrogen, and C-
reactive protein, as well as results of renal ultrasound, lung
X-ray, and echocardiogram were recorded for each neonate
as part of routine care. Duration of mechanical ventilation,
medications, and 28-day mortality were also recorded. Body
weight, body length, total fluid administration, and urine
output were recorded at sampling during the first 10 days of
life.
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Diagnosis of AKI was based on serum Cr>1.5 mg/dl
(132.6 μmol/l) on the first 3 days of life (sustained at least
48 h, the mother of the neonate has normal renal function)
and on the modified pediatric RIFLE (pRIFLE) classifica-
tion after the first 3 days of life. Estimated Cr clearance
(eCCl) was calculated using the Schwartz formula [29, 30].
The pRIFLE classification has been evaluated in several
pediatric populations: pRIFLE R (Risk) was defined as
a ≥25% decrease in eCCl; pRIFLE I (Injury) as a ≥50%
decrease; and pRIFLE F (Failure) as a ≥75% decrease in
eCCl from baseline renal function [21, 31, 32]. Baseline
eCCl was calculated on the third day of life.
Urine sample collection
Of the total 62 neonates, 41 were admitted to the unit on the
first day of life, 14 on the second day of life, and seven
neonates were admitted to the unit on the third day of life.
Urine samples were collected every 48–72 h during the first
10 days of life.
Measurement of urinary IL-18
After collection, urine was immediately frozen and stored at
−80°C. For the measurement of IL-18, urine was centrifuged at
1,500 × g at 4°C for 10 min, and the supernatants were
aliquoted and measured using a human IL-18 enzyme-linked
immunosorbent assay (ELISA) kit (eBioscience BMS267/2,
Vienna, Austria) that specifically detects the mature form of
IL-18. The cross-reactivity of the kit for pro-IL-18 is extremely
low [13, 33]. The assay was performed according to the man-
ufacturer’s protocol. Briefly, IL-18 standards or samples were
applied onto the precoated microwells. Microwells were then
incubated for 2 h at room temperature and then washed with
washing buffer. In succession, biotin-conjugated anti-human
IL-18 monoclonal antibody and streptavidin-horseradish per-
oxidase were incubated in the wells for 1 h. After washing, a
substrate was added for 10 min in the dark before adding stop
solution. Finally, IL-18 concentration was measured at 450-nm
wavelength in each well. The linearity was observed in
the range of 78–5,000 pg/ml with correlation coefficient
(R
2)>0.998 in this study. The detection limit for IL-18 was
12.5 pg/ml. The coefficient of variation of inter-assay and intra-
assay reproducibility for IL-18 concentration ranges from 5–
11%, corresponding to that reported by the kit manufacturer.
The measurements were also repeated on six ‘standard’ urine
samples that were run together with every set of the patient
samples to confirm the reliability of IL-18 results in this study.
Final uIL-18 values were expressed in picograms per milliliter
( p g / m l )o rp i c o g r a m sp e rm i l l i g r a mo fu r i n a r yC r( p g / m gu C r ) .
Measurement of urinary CysC
The concentration of uCysC from the same samples was
measured on an automatic biochemical analyzer (Hitachi
7600, Tokyo, Japan) by immunoturbidimetry assay and
expressed in nanograms per milliliter (ng/ml) or nanograms
per milligram of urinary Cr (ng/mg uCr). The detection limit
for CysC was 10 ng/ml. The laboratory investigators were
blinded to the sample sources and clinical outcomes. In
addition, urinary Cr was measured automatically by the
Jaffe’s method without deproteinization.
Data management, interpretation, and analysis
The results of uIL-18 and uCysC with and without adjust-
ment for urinary Cr were analyzed.
Determination of whether the level of uIL-18 and uCysC
varies with gestational age and other factors:
The initial and the peak values of urinary biomarkers
were used for association analysis. For each neonate, the
value of IL-18 and CysC from the urine sample collected on
the first day admitted to our unit was denoted as first uIL-18
and first uCysC. Using all samples collected, the highest
uIL-18 and uCysC concentration for each neonate was
denoted as peak uIL-18 and peak uCysC.
We examined the association between the first or peak
value of urinary biomarkers and gestational age, birth
weight, postnatal age, body weight, gender, Apgar score,
or SNAP, in order to determine whether the level of uIL-18
and uCysC varies with gestational age and other factors.
Since AKI may represent a confounding factor, the associ-
ation among these variables was evaluated exclusively in
non-AKI control neonates.
We also compared the peak concentration of uIL-18 or
uCysC between AKI and non-AKI neonates.
Determination of the association between urinary bio-
markers and AKI:
Using the urine samples collected 0–48 h prior to the
clinical diagnosis of AKI and the first urine samples collect-
ed from neonates who did not develop AKI during the study
period, we determined whether uIL-18 and uCysC would
predict the development of AKI within 48 h in non-septic
critically ill neonates.
We also used these urine samples to calculate the diag-
nostic characteristics of uIL-18 and uCysC to predict AKI
development.
Statistical analysis
Statistical analyses were performed using SPSS Statistics
13.0. Assumptions of normality and homogeneity of vari-
ance were first checked. For continuous variables with a
normal distribution, descriptive results were presented as a
Pediatr Nephrol (2012) 27:851–860 853mean and a standard deviation (SD). The t test for unpaired
samples was used to analyze the differences between groups.
For continuous variables with a skewed distribution, descrip-
tive results were expressed as a median and a range. The
Mann–Whitney U test and the two-sample Kolmogorov–
Smirnov test were used to evaluate the differences between
groups. The non-parametric Friedman’s test was performed
for related samples. The concentration of urinary biomarkers
was log-transformed due to a skewed distribution when anal-
ysis of covariance (ANCOVA) was used to adjust for baseline
differences. Categorical variables were expressed as propor-
tions. The significance of differences between proportions or
percentages was determined by the Chi-square test or Fisher's
exact test when the expected value was less than 5. The
relationship between urinary biomarkers and other variables
was assessed by univariate and multiple linear regression
analysis. Linear regression analysis was performed on log-
transformed or square root-transformed data when necessary
tomeettheassumptionofhomogeneityofvariances(Levene's
test). Logistic regression was used to determine whether a
urinary biomarker wasa predictor ofAKIdevelopmentwithin
48 h, independent of potential confounders. Model fit was
assessed with the Hosmer–Lemeshow goodness-of-fit test. A
non-significant value for the Hosmer–Lemeshow Chi-square
test suggests an absence of biased fit. A receiver operating
characteristic(ROC)curvewasconstructedandtheareaunder
the ROC curve (AUC) was calculated to assess the predictive
strength. Optimal cut-off points to maximize both sensitivity
and specificity were also determined. Differences with p val-
ues <0.05 were considered to be statistically significant. All
probability values are two-sided.
Results
Patient characteristics
The study involved 62 neonates. Of a total of 108 neonates
admitted to our unit on the first 3 days of life during the study
period, 46 were excluded: five were diagnosed with culture-
proven sepsis, 31 were clinically diagnosed with sepsis, pneu-
monia, or TORCH syndrome, six underwent exchange trans-
fusion, and fourhad lessthan two serumCrmeasurements.Of
the 62 neonates, 11 fulfilled the criteria for AKI during the
first 10 days of life. Three neonates had serum Cr>1.5 mg/dl
on the first 3 days of life and sustained 48 h (the mother of the
neonate has normal renal function): one on the first day and
two on the third day of life. Eight neonates developed
pRIFLE-I: two on the fourth day of life, one on the fifth,
one on the sixth, and four on the seventh day of life. Clinical
characteristics ofneonateswith and withoutAKI are shown in
Table 1. None of the neonates was born from mothers with
renal dysfunction or diabetes mellitus. All neonates received
cephalosporins.However,noneofthemreceivedaminoglyco-
sides, vancomycin, or ibuprofen. There was a significant
difference in gestational age and birth weight between AKI
and non-AKI neonates. The median of Apgar score at both 1-
and 5-min score was significantly lower in neonates with AKI
as compared with those without AKI. The median of SNAP
and the 28-day mortality was significantly higher in AKI than
in non-AKI neonates.
Urinary biomarkers
A total of 178 samples of a possible 215 samples (83%) were
collected: 16 neonates had four samples, 30 neonates had
three samples, and eight neonates had two samples. Six neo-
nateswere discharged to homebeforethe 10th day oflife. The
missing samples were because of a failure in collecting urine.
Urinary IL-18 was detectable in 113 (64%) samples. Urinary
CysC was detectable in 162 (91%) samples.
The results of uIL-18 and uCysC with adjustment for
urinary Cr are shown in the present study. Although there
was a very similar trend, the results were attenuated some-
what when the absolute value of urinary biomarkers without
adjustment for urinary Cr was analyzed.
Variation of the concentration of uIL-18 and uCysC in non-
AKI control neonates during the first 10 days of life
The effect of postnatal development on the level of urinary
biomarkers during early life was first investigated exclusive-
ly in non-AKI control neonates.
Analysis of the data from non-AKI neonates that had four
urinary samples during the first 10 days of life showed no
significant difference in the level of uIL-18 or uCysC over
the age period (n014, p>0.05, Friedman’st e s tf o rf o u r
related samples). Similar trends were observed in the level
of uIL-18 or uCysC in non-AKI neonates that have at least
three urinary samples during the first 10 days of life (n037,
p>0.05, Friedman’s test for three related samples).
Determination of how the concentration of uIL-18
and uCysC varies with gestational age and other factors
in non-AKI control neonates
Univariate regression analysis demonstrated that neither the
first uIL-18 nor the peak uIL-18 was significantly associated
with gestational age, birth weight, body weight, postnatal
age, gender, 5-min Apgar score, and SNAP in neonates
without AKI. In contrast, both the first and the peak uCysC
were significantly negatively associated with gestational
age, birth weight, and body weight, but not with postnatal
age, gender, 5-min Apgar score, and SNAP. The correlation
analysis of the peak value of urinary biomarkers with
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in non-AKI control neonates is shown in Fig. 1.
In addition, using a stepwise multiple linear regression anal-
ysis, in which uIL-18 or uCysC was modeled with gestational
and postnatal age, body weight, gender, Apgar score, and
SNAP, the concentration of uCysC in non-AKI control neo-
nates was only dependent on gestational age (the first uCysC:
β0−0.520, p00.000; the peak uCysC: β0−0.549, p00.000).
Comparison of the peak value of uIL-18 and uCysC
between AKI and non-AKI neonates
T h ep e a kc o n c e n t r a t i o no fb o t hu I L - 1 8a n du C y s Cw a s
significantly higher in non-septic critically ill neonates with
AKI as compared with non-AKI controls (Fig. 2a and b).
The difference remained significant after controlling for
gestational age, body weight, or gender using ANCOVA.
Association of urinary level of IL-18 and CysC with AKI
To identify whether uIL-18 and uCysC would predict the
development of subsequent AKI in non-septic critically ill
neonates, we analyzed the urine samples collected 0–48 h
prior to the clinical diagnosis of AKI. The results of urinary
biomarkers from the first collected urine samples of life
were used to serve as controls in 51 neonates who did not
develop AKI during the study period.
Logistic regression analysis identified that gestational age
at birth, birth weight, 5-min Apgar score, SNAP, uIL-18, and
uCysC were significantly associated with the development of
AKI. The odds ratio for predicting the development of AKI is
shown in Table 2. The association was further analyzed with
adjustment for potential confounding variables. The 5-min
Apgar score was not significantly associated with AKI after
adjustment for gestational age at birth. The SNAP score,
Table 1 Patient characteristics
Values are mean ± SD or median
[range]
AKI, acute kidney injury; CPAP,
continuous positive airway pres-
sure; NS, not significant; SNAP,
the score for neonatal acute
physiology
p value refers to comparison of
non-AKI and AKI groups
Characteristics Total n062 Non-AKI n051 AKI n011 p value
Gestational age, weeks 34.1±3.2 34.5±2.7 32.2±4.4 0.015
26–28 w, n (%) 3 (5) 1 (2) 2 (18) NS
29–32 w, n (%) 15 (24) 10 (20) 5 (45) NS
33–36 w, n (%) 36 (58) 33 (65) 3 (27) 0.040
37–42 w, n (%) 8 (13) 7 (14) 1 (9) NS
Birth weight, g 2,064±616 2,161±595 1,617±521 0.008
Small for gestational age, n (%) 4 (6) 2 (4) 2 (18) NS
Gender (male ⁄ female) 34/28 25/26 9/2 NS
Apgar score, 1 min 9 [2–10] 9 [2–10] 7 [4–10] 0.013
Apgar score, 5 min 9.5 [3–10] 10 [5–10] 9 [3–10] 0.008
Apgar score at 5 min ≤7 7 (11) 5 (10) 2 (18) NS
SNAP 12 [5–27] 10 [5–21] 16 [7–27] 0.018
Oliguria, n (%) 2 (3) 0 (0) 2 (18) 0.029
Apnea, n (%) 2 (3) 1 (2) 1 (9) NS
Respiratory distress syndrome, n (%) 6 (10) 2 (4) 4 (36) 0.007
Congenital heart disease, n (%) 3 (5) 3 (6) 0 (0) NS
Hypoxic ischemic encephalopathy, n (%) 8 (13) 6 (12) 2 (18) NS
Intraventricular hemorrhage, n (%) 2 (3) 1 (2) 1 (9) NS
Necrotizing enterocolitis, n (%) 1 (2) 1 (2) 0 (0) NS
CPAP, n (%) 16 (29) 10 (20) 6 (55) 0.026
Mechanical ventilation, n (%) 10 (16) 5 (10) 5 (45) 0.011
Surfactant treatment, n (%) 6 (10) 3 (6) 3 (27) NS
Diuretics, n (%) 7 (11) 6 (12) 1 (9) NS
Dopamine, n (%) 20 (32) 13 (25) 7 (64) 0.029
Aminophylline, n (%) 6 (10) 3 (6) 3 (27) NS
Postnatal steroids, n (%) 1 (2) 1 (2) 0 (0) NS
Phototherapy, n (%) 8 (13) 6 (12) 2 (18) NS
28-day mortality, n (%) 4 (6) 1 (2) 3 (27) 0.016
Maternal characteristics
Pre-eclampsia, n (%) 6 (10) 4 (8) 2 (18) NS
Hypertension, n (%) 2 (3) 2 (4) 0 (0) NS
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justmentforthesamevariable,andafterfurtheradjustmentfor
postnatal age, birth weight, gender, and 5-min Apgar score.
The level of uIL-18 and uCysC remained predictive of AKI
development after adjustment for potential confounders,
including gestational and postnatal age, birth weight, gender,
5-min Apgar score, and SNAP.
Ability of urinary level of IL-18 and CysC to predict AKI
The diagnostic performance of urinary biomarkers on pre-
dicting AKI development is assessed in Table 3. The level of
uIL-18 was predictive of the development of AKI within
4 8h( A U C 00.72, p00.021). Urinary CysC was highly
predictive of AKI, which displayed the best predictive per-
formance, had odds ratio of 2.07, and achieved AUC of 0.92
for predicting the development of AKI within 48 h. In
Fig. 3, we show that uCysC was better than uIL-18 or SNAP
in predicting the development of AKI.
We also calculated the cut-off value for urinary biomarkers
to predict the development of AKI within 48 h in Table 3.
Urinary IL-18 displayed sensitivity of 64% and specificity of
92% at the optimal cut-off value of 1,800 pg/mg uCr. The
positiveandnegativelikelihoodratioswere8.0and0.4.Atthe
concentration ofuCysC≥2,500 ng/mg uCr, the sensitivity and
specificity for detecting AKI within 48 h were 91% and 86%,
and the positive and negative likelihood ratios were 6.5 and
0.1, respectively.
Discussion
Our data demonstrate that AKI is characterized by high levels
of uIL-18 and uCysC, which fits our hypothesis. Both uIL-18
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data from non-AKI (acute
kidney injury) control neonates
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856 Pediatr Nephrol (2012) 27:851–860and uCysC are predictive of subsequent development of AKI
in non-septic critically ill neonates, independent of potential
confounders.
The present study examines the impact of gestational and
postnatal age, birth weight, gender, Apgar score, and SNAP
on the utility of uIL-18 and uCysC as an AKI biomarker.
Controlling for these important confounders is essential in
interpreting AKI biomarkers in the context of the clinical
status of the newborns.
Compared to the previous study in premature infants, our
study included a neonatal population with a wide range of
gestational age. Nevertheless, our results are in line with the
previous study [26]. The level of uCysC, but not of uIL-18,
decreased with increasing gestational age and birth weight.
Furthermore, the present study demonstrates that uCysC
decreased with increasing body weight, but not with increas-
ing postnatal age in non-AKI control neonates during early
life. It is well known that there is a significant body water
loss during the first week of life in neonates. The decreased
uCysC level in neonates with increasing gestational age and
body weight might reflect renal maturity. The decreased
excretion of urinary proteins with increasing renal matura-
tion has been well elucidated in previous studies [34–36]. It
may not be surprising that uIL-18 is not associated with
gestational age, body weight, and postnatal age, because
uIL-18 is released in response to renal tubular injury, and
is not a marker of clearance [18].
In addition, there was a significant difference between
AKI and non-AKI neonates with regard to gestational age,
birth weight, Apgar score, respiratory distress syndrome
(RDS), and mechanical ventilation in this study, which is
consistent with previous studies. Low birth weight, low
Apgar score and RDS were identified as independent risk
factors for impaired renal function in neonates [7, 37].
To our knowledge, the present study is the first to exam-
ine the relationship between uIL-18 or uCysC and AKI
Fig. 2 Comparison of the peak level of urinary biomarkers between
non-septic critically ill neonates with AKI (n011) and non-AKI con-
trols (n051). Each circle represents an individual patient and the
horizontal lines indicate median values. Probability values: two-
sample Kolmogorov–Smirnov test
Table 2 Logistic regression analysis of risk factors for acute kidney injury (AKI) development*
OR 95% CI p value Adjusted OR 95% CI p value
Gestational age (weeks) 0.77 0.611–0.980 0.033
Birth weight (g) 0.81
a 0.682–0.950 0.010 0.82
d 0.674–0.998 0.048
Gender 0.21 0.042–1.088 NS 0.23
d 0.044–1.227 NS
Postnatal age (days) 0.94 0.720–1.217 NS 0.88
d 0.650–1.179 NS
Apgar score, 5 min 0.63 0.416–0.959 0.031 0.65
d 0.400–1.054 NS
SNAP 1.20 1.030–1.388 0.019 1.25
e 1.014–1.536 0.037
uIL-18 (pg/mg uCr) 2.27
b 1.245–4.130 0.007 6.15
f 1.459–25.917 0.013
uCysC (ng/mg uCr) 2.07
c 1.302–3.286 0.002 2.18
f 1.158–4.119 0.016
*Urine samples collected 0–48 h prior to the clinical diagnosis of AKI and the first urine samples collected from neonates who did not develop AKI
during the study period were used for the analysis
CI confidence interval; OR odds ratio; SNAP the score for neonatal acute physiology
aOdds ratios represent the increase in risk per 100 g increase in birth weight
bOdds ratios represent the increase in risk per 1,000 pg/mg increase in uIL-18/uCr
cOdds ratios represent the increase in risk per 1,000 ng/mg increase in uCysC/uCr
dAdjusted for gestational age
eAdjusted for gestational and postnatal age, birth weight, gender and 5 min-Apgar score
fAdjusted for gestational and postnatal age, birth weight, gender, 5 min-Apgar score, and SNAP
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the first week of life. Neonates with systemic infections,
including sepsis, were excluded in the present study, since it
has been suggested that sepsis is significantly associated
with the level of both uIL-18 and uCysC [14, 19]. It is
important to assess potential biomarkers in a heterogeneous
population of critically ill neonates with a wide range of
gestational ages. In this real-world clinical setting, the kid-
ney undergoes growth and maturation, and many risk factors
are correlated with AKI and the timing of kidney injury is
unknown. Focusing on a very early period after birth is also
relevant, since a neonate during the first week of life is in a
different physiological state due to the abrupt change at birth
[36].
Urinary IL-18 is useful for the detection of AKI in non-
septic critically ill neonates in our study, which is in
agreement with a previous report from Washburn et al.,
where urinary IL-18 predicts severity of AKI only in non-
septic critically ill children [21]. The most likely reason for
the discrepancy between our data and the data from Askenazi
et al. [27] is that the neonates with systemic infections, in-
cludingsepsis,wereexcludedinthepresentstudy.Inaddition,
the level of uIL-18 is not influenced by gestational and post-
natal age, body weight, gender, Apgar score, and the severity
of illness assessed by SNAP, which might be considered as
advantages in the clinical utility of uIL-18 as an AKI bio-
marker in the neonatal population.
Urinary CysC is also associated with AKI development
in the study, which is in line with the previous report [27].
One of our major findings was that uCysC displayed better
performance, predicting the development of AKI with great-
er accuracy in non-septic critically ill neonates. One possible
explanation might be that AKI definition is based on serum
Cr, not renal tubular injury. Unlike uIL-18, the level of
uCysC normalized to urinary Cr concentration has been
shown to be a reliable screening tool for detecting decreased
GFR in children [38]. Although CysC is most predominate-
ly reabsorbed from the proximal tubular cells, a detectable
amount is still excreted in urine. The concentration of
uCysC is found to reflect GFR when the ratio of urinary
CysC to urinary Cr is in the normal range [39].
In addition, the performance of SNAP, which was based
on 28 items collected over the first 24 h of admission to
NICU in our study [28], merits further investigation. SNAP
is suggested to be a measure of illness severity and corre-
lates well with neonatal mortality [40]. Our study suggests
that SNAP has the potential to be used in clinical settings as
a method of predicting AKI development during the first
week of life in critically ill neonates.
There were a number of limitations to our study. First, the
definition of AKI in our study was based on the increase in
serum Cr, which remains an accepted and widely used
method for evaluating renal function in NICU. Since there
is the lack of a classification system to define AKI in
neonatal population, the difference in the definition of AKI
might be likely to cause discrepancies when comparing
results across studies. Second, we used the first urine
Table 3 Diagnostic characteristics of SNAP and urinary biomarkers for acute kidney injury (AKI)*
Predictor variable AUC 95% CI p value Optimal cut-off value Sensitivity (%) Specificity (%) LR+ LR–
SNAP 0.73 0.57–0.89 0.018 20 27 96 6.8 0.8
uIL-18 (pg/mg uCr) 0.72 0.52–0.93 0.021 1,800 64 92 8.0 0.4
uCysC (ng/mg uCr) 0.92 0.84–1.00 0.000 2,500 91 86 6.5 0.1
*Urine samples collected 0–48 h prior to the clinical diagnosis of AKI and the first urine samples collected from neonates who did not develop AKI
during the study period were used for the analysis
AUC area under the receiver–operating–characteristic curve; CI confidence interval; LR+ likelihood ratio positive; LR– likelihood ratio negative;
SNAP the score for neonatal acute physiology
Fig. 3 Receiver operating characteristic (ROC) curves for the ability of
urinary biomarkers and the score for neonatal acute physiology (SNAP)
to predict acute kidney injury (AKI) development in non-septic critically
ill neonates (n062). The area under the ROC curve for urinary cystatin C
(ng/mg uCr), urinary interleukin-18 (pg/mg uCr), and the score for
neonatal acute physiology (SNAP) were 0.92, 0.72, and 0.73, respectively,
with a Hosmer-Lemeshow goodness-of-fit p value >0.05
858 Pediatr Nephrol (2012) 27:851–860samples prior to the clinical diagnosis of AKI collected from
AKI neonates and the first urine samples of life collected
from neonates who did not develop AKI during the first
10 days of life, which causes discrepancy in postnatal age at
sampling. Notably, the level of neither uIL-18 nor uCysC
was significantly affected by postnatal age. Third, we note
that we did not follow daily urinary biomarkers and serum
Cr as part of the study. The exact timing of kidney injury is
uncertain. This may have led us to underestimate the rate of
AKI and limited our ability to determine the exact time at
which the levels of uIL-18 and uCysC rise prior to serum Cr
increase, and to further evaluate the diagnostic performance
at the time points. Fourth, there was a significantly higher
mortality rate in neonates with AKI as compared with those
without AKI in this study. However, the relatively small
sample size limited our ability to determine whether urinary
biomarkers can predict neonatal mortality.
In conclusion, our study indicates that the level of
uCysC, but not uIL-18, may decrease with increasing renal
maturity of the neonates. Both uIL-18 and uCysC may have
an important role in non-septic critically ill neonates, as a
non-invasive biomarker to independently predict AKI de-
velopment during early life after birth. Urinary CysC could,
as an independent biomarker with greater accuracy than
uIL-18, predict the development of AKI in non-septic crit-
ically ill neonates. Large studies are needed to further ex-
plore the role of urinary biomarkers for detection of AKI in
the neonatal population.
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